Moreover, SEMA6D enhanced anti-tumor immunity by enhancing the infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes into the tumor microenvironment (TME). The gene discussed is CD8A; the disease is neoplasm.